Skip to content

Dr. Peter Libby appointed to the Abcentra Board of Directors. Read the Article.

Abcentra logo
  • Our Company
  • Coronary Artery Disease
  • Orticumab
  • Resources
  • Our Company
  • Coronary Artery Disease
  • Orticumab
  • Resources
  • Contact Us
Previous
  • View Larger Image

Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy

By Lina Yoon|2025-07-24T22:05:40+00:00July 24, 2025|

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail

About the Author: Lina Yoon

Keep up to date on Abcentra’s work

Get press releases and other timely announcements directly to your email inbox.

Thank you for subscribing! We look forward to connecting soon.
There was an error trying to send your message. Please try again later.
Abcentra white logo

© 2025 Abcentra LLC • All Rights Reserved • Terms of Use • Privacy Policy
Abcentra's pharmaceutical products are investigational and not FDA approved.

Page load link
Go to Top